Krissi Haim, Hiersch Liran, Stolovitch Natan, Nitke Shmuel, Wiznitzer Arnon, Peled Yoav
The Helen Schneider Hospital for Women, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Eur J Obstet Gynecol Reprod Biol. 2014 Nov;182:172-6. doi: 10.1016/j.ejogrb.2014.09.026. Epub 2014 Sep 27.
To determine the effectiveness and safety of uterine artery methotrexate (MTX) infusion and embolization combined with systemic MTX for treatment of non-tubal ectopic pregnancy.
We retrospectively reviewed the electronic files of all women admitted to a single tertiary, university-affiliated medical center with a diagnosis of non-tubal (cervical, interstitial or cesarean section scar) ectopic pregnancy, who were treated by a combination of uterine artery MTX infusion and embolization and systemic MTX between January 2001 and March 2014. The treatment protocol included a total of 4 MTX injections in doses of 1 mg/kg/day every other day (days 1, 3, 5, 7 of the protocol) alternating with folinic acid 0.1 mg/kg (days 2, 4, 6, 8). The first or second MTX dose was administered by transcatheter intra-arterial injection during the embolization procedure just before injecting Gelfoam for bilateral uterine artery occlusion, and the remaining doses were given intramuscularly.
During the study period, 25 women underwent uterine artery infusion and embolization combined with systemic MTX treatment for non-tubal ectopic pregnancy. Ten of the pregnancies were cervical, 9 were interstitial, and 6 were cesarean scar pregnancies. Mean gestational age and beta-human chorionic gonadotropin (β-HCG) level at admission were 68.6±12.9 days and 14,179 (range 436-61596) IU/L, respectively. Treatment was successful in 24 patients (96%) with mean β-HCG resolution time of 52.6 (6-147) days. Mild immediate side effects were reported including 8 cases (32%) of abdominal discomfort, 3 cases (12%) of groin or leg pain and 3 cases (12%) of puncture-site local skin infection. No serious immediate side effects such as internal vascular bleeding, sepsis or early liver or renal failure were observed. Among 12 women who stated that they tried to conceive and were more than a year from the treatment, 10 (83.3%) had subsequent pregnancy.
A combination of uterine artery MTX infusion and embolization with systemic MTX seems to be an effective and safe treatment for non-tubal ectopic pregnancies in women who try to conceive.
确定子宫动脉甲氨蝶呤(MTX)灌注及栓塞联合全身应用MTX治疗非输卵管异位妊娠的有效性和安全性。
我们回顾性分析了2001年1月至2014年3月期间,一所大学附属三级医疗中心收治的所有诊断为非输卵管(宫颈、间质部或剖宫产瘢痕处)异位妊娠且接受子宫动脉MTX灌注及栓塞联合全身应用MTX治疗的女性患者的电子病历。治疗方案包括共4次MTX注射,剂量为1mg/kg/天,隔日注射(治疗方案的第1、3、5、7天),同时交替给予亚叶酸0.1mg/kg(第2、4、6、8天)。第一次或第二次MTX剂量在栓塞过程中,于注入明胶海绵进行双侧子宫动脉闭塞前经导管动脉内注射,其余剂量则通过肌肉注射给药。
研究期间,25名女性接受了子宫动脉灌注及栓塞联合全身MTX治疗非输卵管异位妊娠。其中10例为宫颈妊娠,9例为间质部妊娠,6例为剖宫产瘢痕妊娠。入院时平均孕周和β-人绒毛膜促性腺激素(β-HCG)水平分别为68.6±12.9天和14179(范围436 - 61596)IU/L。24例患者(96%)治疗成功,平均β-HCG下降至正常时间为52.6(6 - 147)天。报告有轻度即刻副作用,包括8例(32%)腹部不适、3例(12%)腹股沟或腿部疼痛和3例(12%)穿刺部位局部皮肤感染。未观察到严重即刻副作用,如内血管出血、败血症或早期肝肾功能衰竭。在12名表示尝试受孕且距治疗已超过一年的女性中,10名(83.3%)随后怀孕。
子宫动脉MTX灌注及栓塞联合全身MTX似乎是一种对尝试受孕的女性非输卵管异位妊娠有效且安全的治疗方法。